Your browser doesn't support javascript.
loading
Ventajas de administrar dosis altas de clofazimina / [Advantages of administering high doses of clofazimine]
Butlin, C. Ruth; Maghanoy, Armi.
Affiliation
  • Butlin, C. Ruth; The Leprosy Mission England & Wales. The Leprosy Mission International Bangladesh. Peterborough. UK
  • Maghanoy, Armi; Leonard Wood Memorial Center for Leprosy Research Cebu. Philippines
Fontilles, Rev. leprol ; 33(3): 197-204, Ene.-Jun. 2022. tab
Article in Es | IBECS | ID: ibc-205874
Responsible library: ES1.1
Localization: ES15.1 - BNCS
RESUMEN
A parte de ser un principio activo de la multiterapia (MDT) para la lepra, la clofazimina a mayores dosis se administra para tratar las reacciones de Tipo 2 (ENL) de la lepra. Todavía falta evidencia en los ensayos clínicos sobre las indicaciones, pauta óptima y ratio riesgo/beneficio para apoyar las directrices publicadas sobre su uso como medicamento antileprorreacción. La experiencia clínica indica que, en adultos, la dosis más alta (de 300 mg/ día) es segura durante períodos limitados de tiempo, pero se necesita precaución en individuos de poco peso corporal y en aquellos en tratamiento con otros medicamentos que puedan interaccionar. (AU)
ABSTRACT
Besides its role in multidrug therapy, clofazimine at higher doses is widely used for relief of Type 2 (ENL) reaction in leprosy. There is a lack of evidence from clinical trials regarding indications, optimum regimen and risk/benefit ratio to support published guidelines on its use as an anti-reaction drug. Clinical experience suggests that in adults it is safe at high doses (up to 300 mg/day) for limited periods of time but caution is needed with patients of low body weight and in those taking other drugs which may interact. (AU)
Subject(s)
Key words
Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Clofazimine / Leprosy Limits: Humans Language: Es Journal: Fontilles, Rev. leprol Year: 2022 Document type: Article
Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Clofazimine / Leprosy Limits: Humans Language: Es Journal: Fontilles, Rev. leprol Year: 2022 Document type: Article